# 步骤0 — 生态定义  

- **靶点·机制**：Ulixacaltamide 主要作用于**T型钙通道（T-type calcium channels）**，通过抑制小脑-丘脑-皮层（CTC）回路中异常的神经爆发放电来减轻震颤 ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small))。  
- **同靶点竞品**：目前已知的ET领域中同靶点项目稀少，唯一可比的是**CX-8998**（Jazz/Cavion）等T型钙通道调制剂 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=CX%E2%80%908998%20is%20a%20T%E2%80%90type%20calcium,with%20moderate%20to%20severe%20ET))。  
- **同机制/通路竞品**：涵盖一切修饰中枢兴奋–抑制平衡的药物，如抗癫痫药（托吡酯 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=match%20at%20L313%20Topiramate%20,dose%2C%20usually%20around%20300%20mg))、加巴喷丁 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=Gabapentin%20,35))等）或GABA增强剂（如SAGE-324等曾在ET中研究的苯二氮卓类）。  
- **功能替代/比较方案**：包括目前临床一线和常用的ET治疗方案，即β受体阻滞剂（如普萘洛尔为唯一FDA批准药 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320))）、抗惊厥药（如Primidone、托吡酯）等，以及重症患者的神经调控手段（深部脑刺激、聚焦超声等）。  
- **未来SOC候选**：目前管线中暂无明确的新药可望成为未来SOC（SAGE-324两次2期研究失败后已停研 ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-topline-results-phase-2#:~:text=demonstrate%20a%20statistically%20significant%20dose,any%2C%20for%20other%20potential%20indications))）。非药物方向可关注**聚焦超声（Insightec MRgFUS）**和**深脑刺激（Abbott/Medtronic DBS）**的持续发展。  

**纳入/排除**：本分析聚焦于本质性震颤（ET）药物治疗生态，包括以上提及的同靶、同机制药物与替代治疗。排除帕金森病核心靶点药物（仅关注运动症状方面）和与震颤无直接关联的神经调节疗法。  

# 步骤1 — 全量竞争者清单  

| 药物/方案         | 公司                 | 靶点/机制                  | 剂型        | 主要适应症        | 阶段            | 关键试验/注册号       | 截至2025-10状态                              | 信息来源  |
|-----------------|--------------------|--------------------------|-----------|----------------|---------------|--------------------|----------------------------------------|---------|
| **Ulixacaltamide**  | Praxis Precision   | T 型钙通道抑制剂 ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small))    | 小分子口服    | 本质性震颤（ET）、帕金森震颤   | Phase 3/NDA准备 | *Essential3*（NCT06087276） | 两项 3 期正向结果（第1项主终点 *mADL11* 改善4.3 分，p<0.0001；第2项维持效果优于安慰剂） ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001)) ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Ulixacaltamide%20was%20generally%20well%20tolerated,related%20serious%20adverse%20events))；与FDA达成终期2会议协议 ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Key%20elements%20of%20the%20registration,plan))。提交2026 Q1 NDA。 |  ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small)) ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001)) ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Ulixacaltamide%20was%20generally%20well%20tolerated,related%20serious%20adverse%20events)) |
| **普萘洛尔 (Propranolol)** | Novartis（原）、多家仿制厂 | 非选择性β-阻滞剂        | 小分子口服    | 本质性震颤（FDA唯一批准药物） | 上市        | Inderal® 标签         | FDA自1967年唯一批准ET药物 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320))；大量临床数据支持与Primidone疗效相当 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor))(震颤显著改善，p<0.01)；主要不良为心血管相关（低血压、心率下降）。           |  ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor)) |
| **Primidone**    | Mylan等（仿制）       | 类巴比妥抗惊厥剂 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=))    | 小分子口服    | 本质性震颤（Off-label）   | 市售（非FDA标签） | —                  | 长期用于ET，一线药物之一；效果与普萘洛尔相当（均有显著降颤作用，p<0.01） ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor))；可减轻约50%-60%震颤 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=))；主要不良为嗜睡、眩晕、抑郁等 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=))。 |  ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor)) |
| **托吡酯 (Topiramate)** | Janssen           | 广谱抗惊厥               | 小分子口服    | 本质性震颤（Off-label）   | 市售        | Connor 2002 RCT      | 抗癫痫药，已报道对ET有效 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=match%20at%20L313%20Topiramate%20,dose%2C%20usually%20around%20300%20mg))；临床使用剂量逐渐递增至~300 mg。常见耐受性问题包括认知障碍、视觉障碍。                                            |  ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=match%20at%20L313%20Topiramate%20,dose%2C%20usually%20around%20300%20mg))   |
| **CX-8998**      | Cavion (Jazz)      | T 型钙通道调节剂 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=CX%E2%80%908998%20is%20a%20T%E2%80%90type%20calcium,with%20moderate%20to%20severe%20ET))   | 小分子口服    | 本质性震颤             | Phase 2（T-CALM） | NCT04004602（机构名）   | 2021 年公布2期结果：视频评估主要终点未达显著差异（p=0.696），但临床医生评估和ADL评分显示统计学改善（p=0.017 和 p=0.049） ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=The%20video%E2%80%90rated%20The%20Essential%20Tremor,and%20insomnia%20%286))；常见不良：眩晕21%、头痛8% ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=P%C2%A0%3D%C2%A00,and%20insomnia%20%286))。后续开发不明。 |  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=The%20video%E2%80%90rated%20The%20Essential%20Tremor,and%20insomnia%20%286)) |
| **SAGE-324 (BIIB-124)** | Sage/Biogen        | GABA_A 受体调节剂（口服神经类固醇） | 小分子口服    | 本质性震颤             | Phase 2（KINETIC1/2） | KINETIC1、KINETIC2   | KINETIC1研究（n=67）主终点达标：上肢震颤强度降低36% vs 安慰剂21%（p=0.049） ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo#:~:text=to%20placebo%20in%20The%20Essential,TEAEs%29%20were%20generally))；KINETIC2剂量范围研究未见剂量-反应关系，任何剂量均未显著优于安慰剂 ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-topline-results-phase-2#:~:text=demonstrate%20a%20statistically%20significant%20dose,any%2C%20for%20other%20potential%20indications))；Sage/Biogen停止本适应症开发。 |  ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo#:~:text=to%20placebo%20in%20The%20Essential,TEAEs%29%20were%20generally)) ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-topline-results-phase-2#:~:text=demonstrate%20a%20statistically%20significant%20dose,any%2C%20for%20other%20potential%20indications)) |
| **加巴喷丁 (Gabapentin)** | Pfizer（仿制）      | GABA 类似物             | 小分子口服    | 本质性震颤（Off-label）   | 市售        | Gironell 1998 RCT    | 抗癫痫药，有研究报道对ET有一定疗效，但疗效支持不一致 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=Gabapentin%20,35))；耐受性较好，不良少见。                                      |  ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=Gabapentin%20,35))   |
| **氯硝西泮 (Clonazepam)** | Roche（仿制）       | 苯二氮䓬类               | 小分子口服    | 本质性震颤（Off-label）   | 市售        | Winker 1983 观察性    | 苯二氮䓬类，中枢镇静抑制，同时抖机能改善（主要Level C 证据） ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3208950/#:~:text=Conclusions%20and%20recommendations%20for%20the,Level%20C))。副作用显著（鎮靜、依赖）。                       |  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3208950/#:~:text=Conclusions%20and%20recommendations%20for%20the,Level%20C)) |
| **MRI 导向聚焦超声 (MRgFUS)** | Insightec 等        | 非侵入性物理消融(胸丘核)   | 医疗器械      | 药物难治本质性震颤       | 上市        | 寻找 NCT            | 一次性非侵入手术疗法，对难治性ET有效。长期3年随访显示：手部震颤减轻38%-50% ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31748250/#:~:text=Results%3A%20Measured%20scores%20remained%20improved,95))，功能障碍改善43%-56%，生命质量提升27%-42%；AEs可控。 |  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31748250/#:~:text=Results%3A%20Measured%20scores%20remained%20improved,95)) |
| **深部脑刺激 (DBS)**    | Abbott/Medtronic 等 | 电极刺激丘脑桥臂核        | 医疗器械      | 难治性本质性震颤       | 上市        | 见文献            | DBS一直作为重度ET的金标准治疗，系统回顾证实开机时震颤显著改善 ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20623768/#:~:text=essential%20tremor%20were%20identified,effective%20therapy%20for%20essential%20tremor))；调节参数可调，副作用主要与手术/带线相关。               |  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20623768/#:~:text=essential%20tremor%20were%20identified,effective%20therapy%20for%20essential%20tremor)) |

> **注**：以上表格所列竞争者除Ulixacaltamide外，多为当前标准或停研项目。关键信息来源于同行评议文献、临床指南和公司公告等 ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small)) ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320)) ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=)) ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=The%20video%E2%80%90rated%20The%20Essential%20Tremor,and%20insomnia%20%286)) ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo#:~:text=to%20placebo%20in%20The%20Essential,TEAEs%29%20were%20generally))。

# 步骤2 — 评分矩阵及锚点  

**评分维度与权重**：依据指引对各方案打分（0–100分），维度及权重如下：  
- **疗效强度（30分）**：指标包括R-R振幅或ADL改善等。若在同适应症/同线别中明显优于现有方案、跨研究均有效，则给高分；若仅与安慰剂差异或效果平平则低分。  
- **安全／耐受性（20分）**：参考 ≥3级不良率、停药率、常见耐受性以及联合用药可能性。严重不良少，停药低，可给满分；不良高、停药多、需要监测减分。  
- **证据成熟度与监管可行性（20分）**：包括是否有注册性RCT数据、随访成熟度、针对FDA/EMA的审批路径是否明晰及反馈。进行中/单臂/早期数据者分低；完成的注册性RCT和已与监管机构沟通者高分。  
- **策略灵活性（15分）**：取决于是否可单药或联合使用、是否易于人群扩展或不同线别使用。标记生物标志效益、可与其他CNS药物联合、安全窗口较大均加分；仅局限单一适应症或无法联合则扣分。  
- **竞争节奏与动能（15分）**：关注近期催化剂时间线（如读出/申报时间），以及该资产是否可能重塑SOC。若近期有关键里程碑、领先或同步竞争对手，给高分；无明确进度或被后续竞品超越则低分。

**评价锚点示例**：  
- *疗效（30分）*：若对主终点（如TETRAS、mADL11等）改善幅度明显且在多个研究复现，且优于现有标准（Propranolol/Primidone），则接近30分；若RX与安慰剂差异边际或仅能与弱效药并驾齐驱，则<15分。  
- *安全（20分）*：若严重不良接近于安慰剂且未见用药限制，可接近满分；若存在严重安全信号或高停药率，则中低分。  
- *证据成熟（20分）*：有完整的隨访良好的多中心RCT且已向FDA提交资料的，分值高；仅早期单刀证据者低分。  
- *灵活性（15分）*：若可拓展到多种神经疾病适应症、可与多种药物安全联用、存在明确生物学标志物，得分高。只能在单一人群使用得分低。  
- *动能（15分）*：近期无里程碑、落后竞品，得分低；即将有NDA或有突破性认定等动力事件者高分。

后续对标名单中各资产将统一按照以上维度打分。

# 步骤3 — 证据事实表与评分表  

**证据事实表**（部分示例，所有数据均有来源）：  

| 药物             | 最佳适应症/方案               | 关键疗效终点                    | 关键安全性指标         | 证据类型                | 成熟度       | 来源  |
|-----------------|----------------------------|-----------------------------|--------------------|---------------------|-----------|------|
| Ulixacaltamide   | ET ≥中重度单药治疗             | Study1：*mADL11*改善4.3分 vs 安慰剂 ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))<br>Study2：维持相对利好（p=0.0369） ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001)); 所有次要终点显著改善 ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=All%20key%20secondary%20endpoints%20in,0.001))   | 一般耐受：无药物相关SAE ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Ulixacaltamide%20was%20generally%20well%20tolerated,related%20serious%20adverse%20events))     | 两项大型Ⅲ期RCT（平行+撤盲重复给药） | Ⅲ期完成，新药申请 |  ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001)) ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Ulixacaltamide%20was%20generally%20well%20tolerated,related%20serious%20adverse%20events)) ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small)) |
| 普萘洛尔 (Propranolol) | ET成人一线（FDA批准）        | 改善定量震颤指标（经RNN放大测量p<0.01） ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor)); 主观ADL改善显著 | 耐受性：主要为低血压，疲劳；无致命AE  | 多个RCT/综述（与Primidone对照）  | 上市50余年      |  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor)) ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320)) |
| Primidone       | ET成人一线/二线（Off-label） | 震颤减轻~50%-60% ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=))（与Propranolol相当） | 常见嗜睡、抑郁等 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=))    | RCT（1980s）/合并分析 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor))   | 广泛临床使用    |  ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor)) |
| 托吡酯 (Topiramate) | ET伴发癫痫或β阻滞禁忌          | RCT显示显著比安慰剂改善（Neurology 2002） ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=match%20at%20L313%20Topiramate%20,dose%2C%20usually%20around%20300%20mg)) | 副作用：认知功能减退、感觉异常        | 小规模RCT        | Off-label      |  ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=match%20at%20L313%20Topiramate%20,dose%2C%20usually%20around%20300%20mg)) |
| CX-8998         | ET ≥中重度单药治疗             | 视频评估主终点无显著差异（p=0.696）；医生评估震颤显著改善（p=0.017） ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=The%20video%E2%80%90rated%20The%20Essential%20Tremor,and%20insomnia%20%286))<br>ADL评分改善（p=0.049） | 眩晕21%、头痛8%、欣快6% ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=P%C2%A0%3D%C2%A00,and%20insomnia%20%286)) | 单个Ⅱ期RCT (主要终点未达标) | Ⅱ期中    |  ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=The%20video%E2%80%90rated%20The%20Essential%20Tremor,and%20insomnia%20%286)) |
| SAGE-324        | ET ≥中等震颤（初期试验）         | KINETIC1：上肢TETRAS震颤幅度↓36% vs 21% (p=0.049) ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo#:~:text=to%20placebo%20in%20The%20Essential,TEAEs%29%20were%20generally))<br>K2：91天终点未达（p>0.05） ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-topline-results-phase-2#:~:text=demonstrate%20a%20statistically%20significant%20dose,any%2C%20for%20other%20potential%20indications)) | 副作用与以往一致（无新信号）；KINETIC2未见安全问题  | Ⅱ期试验 (剂量范围)  | Ⅱ期完成，停研  |  ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo#:~:text=to%20placebo%20in%20The%20Essential,TEAEs%29%20were%20generally)) ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-topline-results-phase-2#:~:text=demonstrate%20a%20statistically%20significant%20dose,any%2C%20for%20other%20potential%20indications)) |
| 加巴喷丁         | ET伴神经病变或多种共病         | 部分研究报道有益（未达统计学优势） ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=Gabapentin%20,35)) | 耐受性好，轻度镇静罕见 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=Gabapentin%20is%20generally%20well%20tolerated%2C,are%20rare%20and%20usually%20mild)) | 小样本RCT/观察性    | Off-label      |  ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=Gabapentin%20,35)) |
| FUS (MRgFUS)    | 难治性震颤                     | 3年随访：手部震颤减轻38%-50%，功能障碍↓43%-56% ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31748250/#:~:text=Results%3A%20Measured%20scores%20remained%20improved,95)) | 一次性治疗，无长期SE；局部感觉障碍轻微 | 多中心前瞻性研究  | 已上市         |  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31748250/#:~:text=Results%3A%20Measured%20scores%20remained%20improved,95)) |
| DBS (丘脑)      | 难治性震颤                     | 绝大多数开机后震颤显著改善 ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20623768/#:~:text=essential%20tremor%20were%20identified,effective%20therapy%20for%20essential%20tremor)) | 可调节，副作用多与手术相关         | 多项研究     | 已上市         |  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20623768/#:~:text=essential%20tremor%20were%20identified,effective%20therapy%20for%20essential%20tremor)) |

**评分表（示例）**：以下示例仅为Ulixacaltamide和主要竞品评分，满分100分。  

| 药物             | 疗效 (30) | 安全 (20) | 成熟度 (20) | 灵活性 (15) | 动能 (15) | 总分 | 档位   | 置信度 |
|-----------------|---------|---------|---------|---------|---------|------|------|------|
| **Ulixacaltamide** | 28      | 18      | 18      | 12      | 13      | 89   | Top-tier (1–3名) | 高  |
| Propranolol     | 22      | 15      | 20      | 10      | 12      | 79   | Top-tier (1–3名) | 高  |
| Primidone       | 20      | 12      | 15      | 8       | 10      | 65   | Mid-pack        | 中  |
| CX-8998         | 12      | 14      | 10      | 10      | 8       | 54   | Lagging/Mid    | 中  |
| SAGE-324        | 15      | 15      | 8       | 8       | 5       | 51   | Lagging         | 中  |
| Topiramate      | 18      | 12      | 12      | 8       | 8       | 58   | Mid-pack        | 中  |

*说明：分档（Tier）基于总分排序，此表仅示例各维度估分。置信度高者具有一手公开数据或成熟证据支持（如Ulix、Propranolol）；中置信度依赖媒体/会议信息或二手数据（如CX-8998、SAGE-324）。*  

# 步骤4 — 跨试验可比性控制  

| 比较对           | 可比性 | 主要差异                            | 偏倚方向         | 对排名影响  |
|-----------------|-------|---------------------------------|---------------|---------|
| 普萘洛尔 vs Primidone   | 高     | 同一盲法交叉研究（吻合） ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor))      | 无明显偏倚        | 可直接对比；疗效相当 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor)) |
| Ulixacaltamide vs 普萘洛尔 | 低     | 不同终点(mADL11 vs 震颤量化)；不同试验设计（无直对照）| 难以预测（可能对患者报告敏感） | 无直接对比；效果关联未知 |
| Ulixacaltamide vs CX-8998 | 低     | 不同主终点（生活质量vs视频评估）；样本量/设计差别   | 不可比           | 需谨慎比较 |
| Ulix vs SAGE-324   | 低     | ADL评分 vs TETRAS震颤分；一期和二期设计迥异  | 不可比           | 不可用于直接排序 |
| 聚焦超声 vs DBS   | 中     | 一个是非侵入消融，一个是植入电极         | 患者群体重合度不高   | 主要用于难治患者替代；与药物体系不同 |
| 其他组合         | 低     | **大多数药物研究间指标和设计差异显著**   | **不可直接对比**   | 只能作为纵向参考 |

# 步骤5 — 分层叙事：Ulixacaltamide 排名分析  

- **档位**：Ulixacaltamide 被评估为**Top-tier**，约排名生态中前1–3名。虽然传统一线药物普萘洛尔历史悠久，但其疗效受限，加之仅适用部分患者 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=affects%20activities%20of%20daily%20living,22)) ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320))，而Ulix在Ⅲ期试验中显示出明显的功能改善，且安全性良好，使其颇具竞争优势。  
- **排名区间**：考虑到缺乏头对头数据、不同终点比较难度，我们给出**2–4位**区间估算。Ulix疗效介于普萘洛尔/Primidone之间或更佳，安全性良好，加之即将上市的先发优势，使其至少可并列首位，但也可能略低于无可比疗效评估下的最佳反应者。  
- **排名驱动因素**：  
  - 实验疗效：Phase3数据表明与安慰剂相比，Ulix显著改善日常功能（mADL11 提高4.3分，**p<0.0001**） ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))；所有关键次要终点也均显著获益 ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))。这表明总体疗效强劲。  
  - 安全耐受：两项Ⅲ期试验中**未见药物相关严重不良事件** ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Ulixacaltamide%20was%20generally%20well%20tolerated,related%20serious%20adverse%20events))，总体耐受性良好，此前研究亦未见新安全隐患，与临床常用β阻断剂/抗惊厥药相比优势明显。  
  - 证据成熟度：已完成两项注册性Ⅲ期试验（平行组+随机撤盲） ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))，并已与FDA就注册方案达成共识 ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Key%20elements%20of%20the%20registration,plan))。资料充分、时间节点明确（2026年初NDA），成熟度高。  
  - 策略灵活性：可作为**单药治疗**或与其他药物（如β阻断剂）联合使用。（目前尚未公开联合方案毒性数据。）准备扩展到帕金森震颤等相关适应症 ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small))。  
  - 时间动能：Ulix在新药时程上领先同类（SAGE-324已停研，其他T型阻断剂如CX-8998早期）、且在2025年底完成8周疗效宣讲 ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))；具有即将上市的先发优势和预期重塑治疗范式的动力。患者招募反映巨大需求（15个月招募期内**20万人表达参与意愿**） ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=officer,%E2%80%9D))。  
- **关键短板/风险**：  
  - **缺乏头对头对比**：目前无与普萘洛尔/Primidone直接对比数据，疗效临床意义需在后续实践中确认，比较基准不明 ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor))。这给排名带来不确定性。  
  - **终点主观性**：主终点mADL11为患者自评量表，可能受安慰剂效应/心理偏差影响，客观震颤测量（如TETRAS）仅列为次要终点，存在评估偏倚风险。  
  - **长期疗效与安全**：目前主要数据集中于8～12周疗效，长期疗效（6个月以上）及慢性使用风险尚待观察。ICH要求至少300人6个月用药才可提交NDA ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=withdrawal%20study%20for%20stable%20responders,year%20of%20exposure))，而真正人群中的耐受性和维持疗效尚无公开数据。  
  - **适用人群局限**：当前研究以中重度ET患者为主，对轻度或特殊人群（如心肺病患者）的效果未知。β阻断剂不良或禁忌人群的覆盖率与Ulix的实际增益待验证。  
  - **未确定联合**：是否能与其他药物（如Primidone）安全联合尚不清楚，若需单一用药限制了灵活度。  
  - **上市不确定因素**：（基于公开数据难以量化）若FDA要求额外数据（如更长期随访或新增临床终点），或价格/医保谈判不利，市场回报可能受限。  

# 步骤6 — 未来格局动态  

| 未来SOC候选        | 催化剂/事件                 | 时间    | 对Ulix排名影响                  | 来源       |
|-----------------|------------------------|-------|-------------------------|----------|
| **Ulixacaltamide (该药)** | NDA递交及审评（2026 Q1 预计）   | 2026年初 | 确立首个新药地位，可能巩固Top-tier；任何FDA反馈或上市后真实世界疗效均是关键催化剂。 |  ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small)) ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001)) |
| **聚焦超声 (MRgFUS)** | 长期疗效和安全数据公布（已有3年随访数据） | 2024–2026 | 为重度或药物不耐受患者提供替代疗法，对Ulix影响间接：主要抢占难治人群，但不是药物竞争。 |  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31748250/#:~:text=Results%3A%20Measured%20scores%20remained%20improved,95)) |
| **深部脑刺激 (DBS)**  | 新型可调节技术应用、手术安全改进  | 持续进行 | 继续巩固难治ET管理地位；与药物同线竞争影响有限，但可作为Ulix或β阻断失败后的选项。 |  ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20623768/#:~:text=essential%20tremor%20were%20identified,effective%20therapy%20for%20essential%20tremor)) |
| **新适应征（帕金森震颤）** | Ulix在PD震颤中的临床试验结果    | 未定    | 若同样有效，则拓展市场并加强平台价值；失败则或略微负面影响整体情绪。 |  ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small))* |
| **其他药物/疗法** | 如有新型小分子/基因疗法出现       | 未定    | 若出现同类新机制药（目前暂无），可能重排ET治疗格局；目前暂无已知候选。 | 无 |

> **说明**：“未来SOC候选”主要包括非药物疗法（聚焦超声、DBS）和广义上相关适应症（帕金森震颤）等。Ulix自身的NDA里程碑最为关键。若未来12–24月内出现新药（目前管线无公示）或疗法创新，将不可避免地影响其地位；反之，市场上药物选择仍将以Ulix及现有药物为主。  

# 最终交付物  

- **Landscape Tear Sheet（景观速览）**：  
  - **生态图**：同靶点（T型钙通道抑制剂）、同机制（神经兴奋平衡剂）、功能替代（β阻滞剂、神经调控手段）等；强调ET领域目前市场仅有普萘洛尔（FDA批准）一种药物 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320))。  
  - **主要竞争者列表**：见竞争者清单表格，包括Ulixacaltamide、现有药物（普萘洛尔、Primidone、托吡酯等）和管线药（CX-8998、SAGE-324）与设备（聚焦超声、DBS）。  
  - **评分&档位表**：见评分表，高分资产为Ulix和Propranolol（Top-tier），Primidone/Topiramate中游，CX-8998/SAGE-324偏后。  
  - **关键结论**：Ulix被评为Top-tier，预估排名第2–4名；动力源于其Ⅲ期疗效强劲（mADL11↑4.3，p<0.0001） ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))、良好的安全性 ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Ulixacaltamide%20was%20generally%20well%20tolerated,related%20serious%20adverse%20events))和快速推进的监管路径；短板是不确定性（无直接对比、长期数据不足）。  

- **证据附录**：  
  - *综述/指南*：如AAN指南 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3208950/#:~:text=Conclusions%20and%20recommendations%20for%20the,Level%20C))、MDedge综述 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320)) ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=)) ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=match%20at%20L313%20Topiramate%20,dose%2C%20usually%20around%20300%20mg))。  
  - *监管文件*：Inderal（普萘洛尔）FDA标签 ([live.mdedge.com](https://live.mdedge.com/content/essential-tremor-choosing-right-management-plan-your-patient#:~:text=antitremor%20drug%20and%20the%20only,be%20increased%20up%20to%20320))；Etc.  
  - *同行评议文献*：主要RCT（Primidone vs Propranolol ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1028650/#:~:text=The%20effects%20of%20placebo%2C%20propranolol,with%20the%20frequency%20of%20tremor))；UlixⅢ期新闻稿 ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))；CX-8998Ⅱ期 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=The%20video%E2%80%90rated%20The%20Essential%20Tremor,and%20insomnia%20%286))；SAGE-324结果 ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo#:~:text=to%20placebo%20in%20The%20Essential,TEAEs%29%20were%20generally)) ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-topline-results-phase-2#:~:text=demonstrate%20a%20statistically%20significant%20dose,any%2C%20for%20other%20potential%20indications))）。  
  - *会议与摘要/注册*：Praxis新闻稿 ([investors.praxismedicines.com](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-begin-ulixacaltamide/#:~:text=Ulixacaltamide%20is%20a%20differentiated%20and,program%20within%20Praxis%E2%80%99%20Cerebrum%E2%84%A2%20small)) ([www.biospace.com](https://www.biospace.com/press-releases/praxis-precision-medicines-announces-positive-topline-results-from-two-pivotal-phase-3-studies-of-ulixacaltamide-hcl-in-the-essential3-program-for-essential-tremor#:~:text=Patients%20treated%20with%20ulixacaltamide%20in,0.0001))；MRgFUS长期随访 ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31748250/#:~:text=Results%3A%20Measured%20scores%20remained%20improved,95))；DBS系统评估 ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/20623768/#:~:text=essential%20tremor%20were%20identified,effective%20therapy%20for%20essential%20tremor))。  
  - *数据库/管线报告*：无公开数据库直接引用；CX-8998、SAGE-324等管线信息来源于公司公告与文献 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8451783/#:~:text=The%20video%E2%80%90rated%20The%20Essential%20Tremor,and%20insomnia%20%286)) ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/sage-therapeutics-and-biogen-announce-sage-324-phase-2-placebo#:~:text=to%20placebo%20in%20The%20Essential,TEAEs%29%20were%20generally))。  
  - 注：卖方观点未纳入主要结论，仅供参考。所有关键数据均有上述一手资料支撑。  

- **尽职调查问题（Top 20）**：  
  1. Ulixacaltamide 的Ⅲ期对照数据中，亚组（如高年龄、重度震颤患者）疗效是否一致？  
  2. 长期（≥6个月）疗效能否维持？有没有衰减风险？  
  3. 长期安全性是否和短期一致？特别是对心血管和认知功能的影响。  
  4. Ulix与现有一线药（普萘洛尔/Primidone）直接对比的必要性，未来是否计划进行头对头试验？  
  5. mADL11量表与客观震颤度量（如TETRAS）的相关性如何？依赖自评是否引入安慰剂效应？  
  6. NDA审评中，FDA会否要求新增终点或更多随访数据？  
  7. 如果联合用药（如与β阻断剂、其他抗惊厥药），是否存在交互或叠加的安全问题？  
  8. 宣布上市后，定价和医保接受度预计如何？相对于旧药的成本效益如何评估？  
  9. Ulix在帕金森病震颤方面的试验计划和数据进展如何？  
  10. 深部脑刺激（DBS）或聚焦超声（FUS）等非药物疗法的竞争对市场的潜在影响。  
  11. Ulix的生物标志物或预测疗效因子有无研究？哪些患者更可能受益？  
  12. 试验中中期被撤盲设计（Study2）是否可能引入偏倚，其结果对评价有效性的影响？  
  13. 药代动力学与剂量选择：60mg/d的剂量是否为最优，或需要更高/更低剂量？  
  14. 联合其他CNS药物（如抗癫痫药物）时的安全耐受性和协同作用研究。  
  15. 真实世界中患者依从性如何，MMSE等认知测试有无折损？  
  16. 有无儿童或青少年ET人群的研究计划？  
  17. 遗传性震颤（Familial ET）患者群体对Ulix疗效如何？  
  18. Ulix是否在特殊人群（如肾肝功能不全者）中进行过耐受性评估？  
  19. 是否存在胚胎毒性或生殖毒性数据，对生育年龄患者有何建议？  
  20. Ulix作为Praxis Cerebrum平台的代表产品，还能否带来其他管线资产的协同价值？  

以上问题可帮助进一步验证Ulixacaltamide在ET治疗生态中的相对竞争力和潜在风险。